4-(4-甲基-1-哌嗪)-3-硝基苯甲酸甲酯 | 65715-48-2

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 二嗪烷类
• 中文名称: 4-(4-甲基-1-哌嗪)-3-硝基苯甲酸甲酯
• 英文名称: methyl 4-(4-methylpiperazin-1-yl)-3-nitrobenzoate
• 英文别名: 4-(4-methyl-piperazin-1-yl)-3-nitro-benzoic acid methyl ester
• CAS: 65715-48-2
• 化学式: C₁₃H₁₇N₃O₄
• mdl: MFCD02083000
• 分子量: 279.296
• InChiKey: VRPYNGMXXLTUOL-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  1.5
• 重原子数：
  20
• 可旋转键数：
  3
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.46
• 拓扑面积：
  78.6
• 氢给体数：
  0
• 氢受体数：
  6

反应信息

• 作为反应物：
  描述：

  4-(4-甲基-1-哌嗪)-3-硝基苯甲酸甲酯 在 吡啶 、 tin(II) chloride dihdyrate 作用下， 以 二氯甲烷 、 乙酸乙酯 为溶剂， 反应 14.0h， 生成 methyl 3-(4-fluoro-3-nitrobenzamido)-4-(4-methylpiperazin-1-yl) benzoate
  参考文献：
  名称：

  Structure-based design of ester compounds to inhibit MLL complex catalytic activity by targeting mixed lineage leukemia 1 (MLL1)–WDR5 interaction

  摘要：

  WDR5 is an essential protein for enzymatic activity of MLL1. Targeting the protein-protein interaction (PPI) between MLL1 and WDR5 represents a new potential therapeutic strategy for MLL leukemia. Based on the structure of reported inhibitor WDR5-0103, a class of ester compounds were designed and synthetized to disturb MLL1-WDR5 PPI. These inhibitors efficiently inhibited the histone methyltransferase activity in vitro. Especially, WL-15 was one of the most potent inhibitors, blocking the interaction of MLL1-WDR5 with IC50 value of 26.4 nM in competitive binding assay and inhibiting the catalytic activity of MLL1 complex with IC50 value of 5.4 mu M. Docking model indicated that ester compounds suitably occupied the central cavity of WDR5 protein and recapitulated the interactions of WDR5-0103 and the hydrophobic groups and key amino greatly increased the activity in blocking MLL1-WDR5 PPI. (C) 2016 Elsevier Ltd. All rights reserved.

  DOI：

  10.1016/j.bmc.2016.09.073
• 作为产物：
  描述：

  4-氟-3-硝基苯甲酸 在 氯化亚砜 、 三乙胺 、 N,N-二异丙基乙胺 作用下， 以 二氯甲烷 、 N,N-二甲基甲酰胺 为溶剂， 反应 7.0h， 生成 4-(4-甲基-1-哌嗪)-3-硝基苯甲酸甲酯
  参考文献：
  名称：

  Structure-based design of ester compounds to inhibit MLL complex catalytic activity by targeting mixed lineage leukemia 1 (MLL1)–WDR5 interaction

  摘要：

  WDR5 is an essential protein for enzymatic activity of MLL1. Targeting the protein-protein interaction (PPI) between MLL1 and WDR5 represents a new potential therapeutic strategy for MLL leukemia. Based on the structure of reported inhibitor WDR5-0103, a class of ester compounds were designed and synthetized to disturb MLL1-WDR5 PPI. These inhibitors efficiently inhibited the histone methyltransferase activity in vitro. Especially, WL-15 was one of the most potent inhibitors, blocking the interaction of MLL1-WDR5 with IC50 value of 26.4 nM in competitive binding assay and inhibiting the catalytic activity of MLL1 complex with IC50 value of 5.4 mu M. Docking model indicated that ester compounds suitably occupied the central cavity of WDR5 protein and recapitulated the interactions of WDR5-0103 and the hydrophobic groups and key amino greatly increased the activity in blocking MLL1-WDR5 PPI. (C) 2016 Elsevier Ltd. All rights reserved.

  DOI：

  10.1016/j.bmc.2016.09.073

文献信息

• Bicyclo-pyrazoles active as kinase inhibitors
  申请人：Bandiera Tiziano

  公开号：US09012487B2

  公开（公告）日：2015-04-21

  A compound having formula (I): wherein: R, A, R1 and R2, are as defined in the specification, and pharmaceutical formulas thereof, and methods of use thereof, as Kinase inhibitors.

  具有公式（I）的化合物：其中：R、A、R1和R2如规范中所定义，以及其药学配方和使用方法，作为激酶抑制剂。
• BICYCLO-PYRAZOLES ACTIVE AS KINASE INHIBITORS
  申请人：Bandiera Tiziano

  公开号：US20090136513A1

  公开（公告）日：2009-05-28

  A compound having formula (I): wherein: R, A, R 1 and R 2 , are as defined in the specification, and pharmaceutical formulas thereof, and methods of use thereof, as Kinase inhibitors.

  化合物的化学式为（I）：其中：R，A，R1和R2如规范中所定义，以及其药物配方和作为激酶抑制剂的使用方法。
• 10.1080/14756366.2024.2353711
  作者：Wu, Tingting、Cheng, Hu、Sima, Lijie、Wang, Zhongyuan、Ouyang, Weiwei、Wang, Jianta、Hou, Yunlei、Zhao, Dongsheng、Liao, Weike、Hu, Chujiao

  DOI：10.1080/14756366.2024.2353711

  日期：——

  The PD-1/PD-L1 pathway is considered as one of the most promising immune checkpoints in tumour immunotherapy. However, researchers are faced with the inherent limitations of antibodies, driving the...

  PD-1/PD-L1 通路被认为是肿瘤免疫治疗中最有前途的免疫检查点之一。然而，研究人员面临着抗体的固有局限性，推动了...
• WO2007/99171
  申请人：——

  公开号：——

  公开（公告）日：——
• PRASAD R.; KUMAR G.; BHADURI A. P., INDIAN J. CHEM. <IJOC-AP>, 1977, B 15, NO 7, 652-653
  作者：PRASAD R.、 KUMAR G.、 BHADURI A. P.

  DOI：——

  日期：——